Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetate

Antonia Martinetti, Nicoletta Zilembo, Leonardo Ferrari, Giorgio Massimini, Anna Polli, Ignazia La Torre, Riccardo Giovanazzi, Paola Pozzi, Paolo Bidoli, Daniela De Candis, Ettore Seregni, Emilio Bombardieri, Emilio Bajetta

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p

Original languageEnglish
Pages (from-to)3485-3491
Number of pages7
JournalAnticancer Research
Volume23
Issue number4
Publication statusPublished - Jul 2003

Keywords

  • Aromatase inhibitors
  • Bone metabolism
  • Cancer
  • Exemestane
  • Insulin-like growth factors
  • Postmenopausal breast
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetate'. Together they form a unique fingerprint.

Cite this